Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 2:44 PM
Ignite Modification Date:
2025-12-24 @ 2:44 PM
NCT ID:
NCT05469659
Eligibility Criteria:
Inclusion Criteria:
* Type 2 diabetic patients
* Patients aged 20 years or older at the time of obtaining consent
* Patients with HbA1c 6.5 or more and 9.0% or less within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor / metformin)
* Patients who have been judged by their doctor to need a diabetic drug when they are first seen, or who have already taken a diabetic drug and have decided that it is necessary to add one diabetic drug.
* Patients who have been receiving RAS inhibitors (ARB, ARNI, ACE inhibitors, direct renin inhibitors) for 4 weeks or longer
* Patients with eGFR of 30 or more (mL / min / 1.73m2) within 13 weeks before obtaining consent (evaluated by test values after 4 weeks or more without taking SGLT2 inhibitor / metformin)
* Patients with urinary albumin / creatinine ratio (UACR) of 30 or more and less than 2000 (mg / gCr) (4 weeks or more without taking SGLT2 inhibitor / metformin) within 13 weeks before obtaining consent Evaluate by inspection value)
* Patients for whom written consent was obtained based on the patient's free will after receiving sufficient explanation for participation in this study
Exclusion Criteria:
* Patients receiving treatment with SGLT2 inhibitor or metformin within 13 weeks before obtaining consent
* Dialysis patient
* Patients with a history of severe hypoglycemia
* Patients with hypersensitivity to SGLT2 inhibitor or metformin
* Pregnant women, lactating patients, and patients who wish to raise children
* Patients with BMI of 35 kg / m2 or more based on the latest measured values within 13 weeks before obtaining consent
* Patients who are contraindicated for the study drug
* Other patients who the attending physician deems inappropriate as a subject
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT05469659
Study Brief:
Protocol Section:
NCT05469659